#United States #Class Action #New Orleans #Kahn Swick #Ultragenyx

Ultragenyx Pharmaceutical Investor Alert

In a significant legal development, Kahn Swick & Foti, LLC (KSF), a well-regarded boutique securities litigation firm, is calling attention to a vital deadline for investors in Ultragenyx Pharmaceutical Inc. This call to action comes on the heels of a securities class action lawsuit initiated against the company, which has raised alarm among affected investors.

The Background of the Case

The securities fraud allegations involve incidents that transpired between August 3, 2023, and December 26, 2025. The lawsuit seeks to represent investors who may have suffered losses linked to these events. Specifically, Ultragenyx faced setbacks regarding its phase 3 clinical trials for setrusumab (UX143), a drug intended to treat Osteogenesis Imperfecta. On December 26, 2025, the company announced that the trials did not yield statistically significant results in reducing fracture rates, leading to a notable drop in the company's stock price by approximately 42% within a short period. The stock plummeted from $34.19 just before the announcement to $19.72 shortly after, sparking questions about the company's practices and handling of information related to the drug’s efficacy.

The Class Action Lawsuit

The legal proceedings, identified as the case of Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., [case number: 26-cv-01097], aim to hold the company accountable for protection against alleged fraudulent activities that negatively impacted its share value. Investors are encouraged to take prompt action if they invested in Ultragenyx during the pertinent timeframe, as there is a limited window to be appointed as lead plaintiffs in this class action lawsuit. Interested parties have until April 6, 2026, to act, though it is important to note that participation in the recovery process does not necessarily rely on taking on the lead plaintiff role.

What Investors Should Do

For shareholders or potential members of the claimant class looking for further details, they should reach out to Lewis Kahn, a managing partner at KSF. Investors are invited to connect either by phone at 1-877-515-1850 or via email at email protected]. Additionally, more information can be accessed through the KSF website at [www.ksfcounsel.com/cases/nasdaqgs-rare/.

About Kahn Swick & Foti, LLC

KSF has garnered a solid reputation within the legal community, providing services to a broad range of clients, including both institutional and individual investors. The firm specializes in recovering losses stemming from corporate fraud or other misconduct. Their track record positions them as one of the top securities litigation law firms in the United States. Notably, KSF was recently ranked among the top ten plaintiffs' law firms based on total settlement value achieved on behalf of their clients.

Conclusion

As the deadline approaches in early April 2026, Ultragenyx investors are strongly urged to assess their legal options with Kahn Swick & Foti, especially if they experienced financial losses due to the alleged misconduct. Staying informed and taking timely action could be key to securing a potential recovery from this ongoing class action lawsuit.